Add Yahoo as a preferred source to see more of our stories on Google. The creation of this new approach to stopping bleeding has unparalleled potential if moved forward in the medical industry, and ...

Hemab Therapeutics, a late stage clinical biotechnology company developing novel prophylactic therapeutics for serious, underserved coagulation disorders, today announced that the U.S. Food and Drug ...

Sutacimig is an investigational bispecific antibody designed to bind to endogenous factor VIIa and localize it to activated platelets, thereby promoting thrombin and fibrin formation.

FDA Breakthrough-designated device under evaluation for treatment of life-threatening abdominal bleeding at leading U.S.